Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
18
pubmed:dateCreated
2001-8-24
pubmed:abstractText
Celecoxib (13) and rofecoxib (17) analogues, in which the respective SO2NH2 and SO2Me hydrogen-bonding pharmacophores were replaced by a dipolar azido bioisosteric substituent, were investigated. Molecular modeling (docking) studies showed that the azido substituent of these two analogues (13, 17) was inserted deep into the secondary pocket of the human COX-2 binding site where it undergoes electrostatic interaction with Arg(513). The azido analogue of rofecoxib (17), the most potent and selective inhibitor of COX-2 (COX-1 IC(50) = 159.7 microM; COX-2 IC(50) = 0.196 microM; COX-2 selectivity index = 812), exhibited good oral antiinflammatory and analgesic activities.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents..., http://linkedlifedata.com/resource/pubmed/chemical/Azides, http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 1, http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2, http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2 Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes, http://linkedlifedata.com/resource/pubmed/chemical/Lactones, http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin-Endoperoxide Synthases, http://linkedlifedata.com/resource/pubmed/chemical/Ptgs1 protein, rat, http://linkedlifedata.com/resource/pubmed/chemical/Pyrazoles, http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides, http://linkedlifedata.com/resource/pubmed/chemical/Sulfones, http://linkedlifedata.com/resource/pubmed/chemical/celecoxib, http://linkedlifedata.com/resource/pubmed/chemical/rofecoxib
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0022-2623
pubmed:author
pubmed:issnType
Print
pubmed:day
30
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3039-42
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11520213-Administration, Oral, pubmed-meshheading:11520213-Animals, pubmed-meshheading:11520213-Anti-Inflammatory Agents, Non-Steroidal, pubmed-meshheading:11520213-Azides, pubmed-meshheading:11520213-Cyclooxygenase 1, pubmed-meshheading:11520213-Cyclooxygenase 2, pubmed-meshheading:11520213-Cyclooxygenase 2 Inhibitors, pubmed-meshheading:11520213-Cyclooxygenase Inhibitors, pubmed-meshheading:11520213-Drug Design, pubmed-meshheading:11520213-Isoenzymes, pubmed-meshheading:11520213-Lactones, pubmed-meshheading:11520213-Membrane Proteins, pubmed-meshheading:11520213-Models, Molecular, pubmed-meshheading:11520213-Prostaglandin-Endoperoxide Synthases, pubmed-meshheading:11520213-Pyrazoles, pubmed-meshheading:11520213-Rats, pubmed-meshheading:11520213-Structure-Activity Relationship, pubmed-meshheading:11520213-Sulfonamides, pubmed-meshheading:11520213-Sulfones
pubmed:year
2001
pubmed:articleTitle
Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere.
pubmed:affiliation
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't